Impact of once-weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, randomised controlled STEP 5 trial

被引：0
|
作者：
Dimitriadis, Georgios K. [1 ]
Batterham, Rachel [2 ]
Bhatta, Meena [3 ]
Holst-Hansen, Thomas [3 ]
Kandler, Kristian [3 ]
Rigas, Georgia [4 ]
Garvey, W. Timothy [5 ]
机构：
[1] Kings Coll London, London, England
[2] UCL, Div Med, Obes Res Ctr, London, England
[3] Novo Nordisk AS, Soborg, Denmark
[4] St George Private Hosp, Dept Bariatr Metab Surg, Kogarah, NSW, Australia
[5] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA
来源：
OBESITY SURGERY | 2023年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S119 / S119
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
    Shi, Aixin
    Xie, Panpan
    Nielsen, Lasse Lykke
    Skjoth, Trine Vang
    He, Xuemei
    Haugaard, Sine Pfeiffer
    ADVANCES IN THERAPY, 2021, 38 (01) : 550 - 561
  • [32] Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
    Verma, Subodh
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John E.
    Garvey, W. Timothy
    Jensen, Camilla
    Kandler, Kristian
    Kushner, Robert F.
    Rubino, Domenica M.
    Kosiborod, Mikhail N.
    ECLINICALMEDICINE, 2023, 55
  • [33] Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
    Aixin Shi
    Panpan Xie
    Lasse Lykke Nielsen
    Trine Vang Skjøth
    Xuemei He
    Sine Pfeiffer Haugaard
    Advances in Therapy, 2021, 38 : 550 - 561
  • [34] Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
    Davies, Melanie
    Faerch, Louise
    Jeppesen, Ole K.
    Pakseresht, Arash
    Pedersen, Sue D.
    Perreault, Leigh
    Rosenstock, Julio
    Shimomura, Iichiro
    Viljoen, Adie
    Wadden, Thomas A.
    Lingvay, Ildiko
    LANCET, 2021, 397 (10278): : 971 - 984
  • [35] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    DIABETES, 2021, 70
  • [36] Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China
    Ji, Linong
    Lu, Yibing
    Shen, Zewei
    Hu, Ping
    Liu, Wenyan
    Zhang, Qiu
    Shi, Bimin
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5312 - 5324
  • [37] Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials
    Mann, Johannes F. E.
    Hansen, Thomas
    Idorn, Thomas
    Leiter, Lawrence A.
    Marso, Steven P.
    Rossing, Peter
    Seufert, Jochen
    Tadayon, Sayeh
    Vilsboll, Tina
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (11): : 880 - 893
  • [38] Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina, I
    Tentolouris, Nikolaos
    Buse, John B.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (09): : 563 - 574
  • [39] Transition from Basal Bolus to Once-Weekly Subcutaneous Semaglutide and Basal Insulin in Patients with Type 2 Diabetes Mellitus (TRANSITION-T2D)-A Prospective Randomized Controlled Trial
    Rodriguez, Paloma
    Breslaw, Nikki
    Bena, James F.
    Xiao, Huijun
    Jenkins, Kimberly
    Isaacs, Diana
    Zhou, Keren
    Griebeler, Marcio L.
    Burguera, Barto
    Pantalone, Kevin M.
    DIABETES, 2023, 72
  • [40] Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial
    Hansen, Morten S.
    Woelfel, Eva M.
    Jeromdesella, Shakespeare
    Moller, Jens-Jakob K.
    Ejersted, Charlotte
    Jorgensen, Niklas R.
    Eastell, Richard
    Hansen, Stinus G.
    Frost, Morten
    ECLINICALMEDICINE, 2024, 72
12345